epirubicin accord 2 mg/ ml
accord healthcare b.v. - epirubicinhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
epirubicin actavis 2 mg/ ml
actavis group ptc ehf - epirubicinhydroklorid - injeksjonsvæske, oppløsning - 2 mg/ ml
epirubicin actavis 10 mg
actavis group ptc ehf - epirubicinhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 10 mg
epirubicin actavis 50 mg
actavis group ptc ehf - epirubicinhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 50 mg
epirubicin medac 2 mg/ ml
medac gesellschaft für klinische spezialpräparate mbh - epirubicinhydroklorid - injeksjonsvæske, oppløsning - 2 mg/ ml
sunitinib sandoz 12.5 mg
sandoz - københavn - sunitinib - kapsel, hard - 12.5 mg
sunitinib sandoz 25 mg
sandoz - københavn - sunitinib - kapsel, hard - 25 mg
sunitinib sandoz 50 mg
sandoz - københavn - sunitinib - kapsel, hard - 50 mg
sunitinib newbury 50 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 50 mg